Short Interest in Silexion Therapeutics Corp (NASDAQ:SLXN) Declines By 87.8%

Silexion Therapeutics Corp (NASDAQ:SLXN) was the recipient of a large drop in short interest in August. As of August 31st, there was short interest totaling 14,501 shares, a drop of 87.8% from the August 15th total of 119,287 shares. Approximately 0.3% of the shares of the stock are sold short. Based on an average daily trading volume, of 257,490 shares, the days-to-cover ratio is presently 0.1 days.

Analyst Upgrades and Downgrades

Several research firms have commented on SLXN. Maxim Group lowered Silexion Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 29th. Weiss Ratings restated a “sell (e+)” rating on shares of Silexion Therapeutics in a research report on Monday, June 15th. One investment analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Silexion Therapeutics currently has a consensus rating of “Hold”.

Silexion Therapeutics Price Performance

NASDAQ SLXN traded down $0.06 during trading hours on Friday, hitting $0.36. 2,534,701 shares of the company’s stock traded hands, compared to its average volume of 6,188,877. The company has a market capitalization of $2.00 million, a PE ratio of -0.01 and a beta of -0.36. Silexion Therapeutics has a 52-week low of $0.34 and a 52-week high of $46.94. The firm’s 50-day moving average is $1.39 and its 200-day moving average is $6.15.

Silexion Therapeutics (NASDAQ:SLXN) last issued its earnings results on Saturday, August 15th. The company reported ($5.17) earnings per share for the quarter, topping the consensus estimate of ($21.20) by $16.03. Equities research analysts predict that Silexion Therapeutics will post -45.5 earnings per share for the current fiscal year.

Silexion Therapeutics Company Profile

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.